CN103119058A - 由血浆生产间-α-抑制蛋白(IAIP) - Google Patents

由血浆生产间-α-抑制蛋白(IAIP) Download PDF

Info

Publication number
CN103119058A
CN103119058A CN2011800457670A CN201180045767A CN103119058A CN 103119058 A CN103119058 A CN 103119058A CN 2011800457670 A CN2011800457670 A CN 2011800457670A CN 201180045767 A CN201180045767 A CN 201180045767A CN 103119058 A CN103119058 A CN 103119058A
Authority
CN
China
Prior art keywords
iaip
composition
ialp
precipitate
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800457670A
Other languages
English (en)
Chinese (zh)
Inventor
S·F·贝尔斯托
J·哈策尔
S·拉马钱德兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of CN103119058A publication Critical patent/CN103119058A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN2011800457670A 2010-07-23 2011-07-22 由血浆生产间-α-抑制蛋白(IAIP) Pending CN103119058A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36733110P 2010-07-23 2010-07-23
US61/367,331 2010-07-23
PCT/US2011/045099 WO2012012773A1 (en) 2010-07-23 2011-07-22 Manufacture of inter -alpha - inhibitor proteins (iaip) from plasma

Publications (1)

Publication Number Publication Date
CN103119058A true CN103119058A (zh) 2013-05-22

Family

ID=44534634

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800457670A Pending CN103119058A (zh) 2010-07-23 2011-07-22 由血浆生产间-α-抑制蛋白(IAIP)

Country Status (14)

Country Link
US (2) US8841248B2 (enExample)
EP (1) EP2596014B1 (enExample)
JP (1) JP5830096B2 (enExample)
KR (1) KR20130093607A (enExample)
CN (1) CN103119058A (enExample)
AU (1) AU2011280907B2 (enExample)
BR (1) BR112013001753A2 (enExample)
CA (1) CA2806645A1 (enExample)
CO (1) CO6680653A2 (enExample)
EA (1) EA201390156A1 (enExample)
ES (1) ES2717177T3 (enExample)
MX (1) MX2013000958A (enExample)
SG (1) SG187599A1 (enExample)
WO (1) WO2012012773A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046587A2 (en) 2003-11-08 2005-05-26 Prothera Biologics Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP2291654B1 (en) 2008-05-28 2018-04-11 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from blood
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
BR112013001753A2 (pt) 2010-07-23 2016-05-31 Baxter Healthcare Sa método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.
TWI629283B (zh) 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
CA2885604A1 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of ischemia using inter-alpha inhibitor proteins
US20140206844A1 (en) * 2013-01-18 2014-07-24 Prothera Biologics Methods for isolating blood products from an inter-alpha inhibitor protein-depleted blood product material
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
EP3512539A4 (en) 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
US20200057077A1 (en) 2017-04-25 2020-02-20 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
SG11202003793WA (en) 2017-10-30 2020-05-28 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
WO2020086879A1 (en) * 2018-10-24 2020-04-30 Prothera Biologics, Inc. Inter-alpha inhibitor proteins and methods of use thereof
CN114096558B (zh) * 2019-07-04 2024-10-01 德国杰特贝林生物制品有限公司 纯化c1-inh的方法
WO2021202373A1 (en) * 2020-03-31 2021-10-07 Baxalta Incorporated A method to produce an immunoglobulin preparation from c-1 inhibitor depleted plasma
CN116322920A (zh) * 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii
CA3198925A1 (en) 2020-11-16 2022-05-19 Yow-Pin Lim Methods for purifying inter-alpha inhibitor proteins
EP4518875A1 (en) * 2022-05-02 2025-03-12 Takeda Pharmaceutical Company Limited Methods of preparing cohn pool concentrate from blood plasma through ultrafiltration

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
CN1153063A (zh) * 1995-09-22 1997-07-02 瑞士红十字会创立血液捐赠服务中央实验室 从人血浆分部分离过程产生的馏分中回收免疫球蛋白的方法
CN101160133A (zh) * 2004-11-05 2008-04-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK166763C (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
JP2004511492A (ja) 2000-10-13 2004-04-15 オクタファルマ　アクチェン　ゲゼルシャフト ビクニンを含む血漿画分、その調製方法、およびその使用
WO2005046587A2 (en) * 2003-11-08 2005-05-26 Prothera Biologics Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP2291654B1 (en) * 2008-05-28 2018-04-11 Prothera Biologics, Inc. Preparation and composition of inter-alpha inhibitor proteins from blood
AT514675B1 (de) * 2009-07-23 2019-05-15 Baxalta Inc Herstellung von faktor h (fh) und fh-derivaten aus plasma
AU2010202125B1 (en) * 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
BR112013001753A2 (pt) 2010-07-23 2016-05-31 Baxter Healthcare Sa método para preparar uma composição d einter-alfa-inibidor (iaip) eriquecida de plasma, solução aquosa de iaip, e, método para tratar uma doença ou distúrbio associado com disfunção de iaip e associado com atividadede protease de serina no plasma aumentada.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2390074A (en) * 1942-02-09 1945-12-04 Research Corp Protein product and process
CN1153063A (zh) * 1995-09-22 1997-07-02 瑞士红十字会创立血液捐赠服务中央实验室 从人血浆分部分离过程产生的馏分中回收免疫球蛋白的方法
CN101160133A (zh) * 2004-11-05 2008-04-09 普罗瑟拉生物公司 治疗用途的来自人血浆的内-α抑制剂蛋白质的制备和组合物
WO2008113589A1 (en) * 2007-03-20 2008-09-25 Csl Behring Gmbh Methods for industrial scale production of therapeutic complement factor h preparations from human plasma

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109867717A (zh) * 2019-04-01 2019-06-11 山西瑞亚力生物技术有限公司 一种血浆中α1微球蛋白的提取方法

Also Published As

Publication number Publication date
EP2596014B1 (en) 2018-11-28
US9505814B2 (en) 2016-11-29
US8841248B2 (en) 2014-09-23
MX2013000958A (es) 2013-11-20
EA201390156A1 (ru) 2014-01-30
CO6680653A2 (es) 2013-05-31
AU2011280907B2 (en) 2016-02-04
ES2717177T3 (es) 2019-06-19
US20150045538A1 (en) 2015-02-12
CA2806645A1 (en) 2012-01-26
KR20130093607A (ko) 2013-08-22
WO2012012773A1 (en) 2012-01-26
AU2011280907A1 (en) 2013-02-07
BR112013001753A2 (pt) 2016-05-31
JP2013535468A (ja) 2013-09-12
JP5830096B2 (ja) 2015-12-09
US20120053113A1 (en) 2012-03-01
EP2596014A1 (en) 2013-05-29
SG187599A1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
CN103119058A (zh) 由血浆生产间-α-抑制蛋白(IAIP)
CN103068365B (zh) 通过用微细分的二氧化硅处理去除丝氨酸蛋白酶
CA2694854C (en) Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
KR101930582B1 (ko) 혈장으로부터 면역글로빈의 분획 i-iv-1 침전
WO2011150284A2 (en) Removal of serine proteases by treatment with finely divided silicon dioxide
CN115397847A (zh) 由c-1抑制剂耗尽的血浆生产免疫球蛋白制剂的方法
US20140275496A1 (en) Isolation of factor h from fraction i paste
HK40079365A (en) Removal of serine proteases by treatment with finely divided silicon dioxide
HK1215931B (zh) 从血浆制备富含igg的组合物的方法
HK1183449B (en) Removal of serine proteases by treatment with finely divided silicon dioxide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130522